| |
Germany approves use of Femara as breast cancer treatmentBreast cancer news 3/7/2005 Novartis pharmaceutical company Monday announced that its breast cancer drug Femara has received marketing authorization in Germany for women who have completed 5 years of Tamoxifen. This approval comes as the result the landmark MA-17 study, an independent, internationally conducted trial that included more than 5,100 postmenopausal women, which was coordinated by the National Cancer Institute of Canada Clinical Trials Group at Queens University in Kingston, Ontario, and supported by Novartis. This study showed that Femara reduced the risk of cancer recurrence by 42%. Femara also reduced the chance of breast cancer returning to another part of the body, or distant metastases, by 39%. The term extended adjuvant describes the period following standard adjuvant, or post-surgery treatment with Tamoxifen. |